NASDAQ
97.42USD
+2.78 (+2.94%)
We have scored 74 news catalysts on GeneDx Holdings Corp. (WGS) over the past 12 months. The biggest single-day move next to one of them came Jun 5, 2026, when WGS closed −7.2%: “GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman”. Coverage across the window leans negative (average ticker sentiment −0.83). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.9B
P/E
—
EPS
—
Beta
2.01
52W range
32.21-170.87
Day range
94.23–99.86
Open
94.23
Prev close
94.64
Volume
785.9K
Avg volume
1.2M
Dividend
0.00
IPO
2020-11-04
Analysts publish price targets on WGS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
8 analyst price targets from $63 to $90
as of 2026-08-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about GeneDx Holdings Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for WGS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
The reconstruction
The current price sits at the very top of the published analyst target range ($63 to $90), fully endorsing the most optimistic models and explicitly rejecting the five lower targets that assume the recent drop in average reimbursement rates is a permanent shift.
What the disagreement turns on
Will the average reimbursement rate per test recover toward $3,500, or will the adverse shift toward lower-ARR genome tests keep it near $3,300? The wired data can measure segment revenue volumes to track the exome-to-genome mix shift, but it cannot directly measure the average reimbursement price.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $90.29 on 2026-08-27 — the quote has since moved +8%, so read this as a record of what was priced in then, not now.
